Greenup Street Wealth Management LLC Takes Position in Eli Lilly and Company $LLY

Key Points

• Greenup Street Wealth Management established a new position in Eli Lilly, buying 2,516 shares in Q4 worth about $2.70 million, while institutional and hedge-fund ownership of the stock is roughly 82.53%.
• Eli Lilly beat quarterly estimates (EPS $7.54; revenue $19.29B, +42.6% YoY), set FY2026 guidance at 33.500–35.000 EPS, and carries a MarketBeat consensus of "Moderate Buy" with an average price target of $1,224.59, supported by momentum from its new obesity pill and recent strategic deals.

Greenup Street Wealth Management LLC bought a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 2,516 shares of the company's stock, valued at approximately $2,704,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of LLY. Brighton Jones LLC grew its holdings in shares of Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock valued at $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC grew its holdings in shares of Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock valued at $1,136,000 after purchasing an additional 40 shares in the last quarter. Schnieders Capital Management LLC. grew its holdings in shares of Eli Lilly and Company by 16.7% in the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company's stock valued at $6,231,000 after purchasing an additional 1,141 shares in the last quarter. Flow Traders U.S. LLC purchased a new position in shares of Eli Lilly and Company in the second quarter valued at $356,000. Finally, Nebula Research & Development LLC purchased a new position in shares of Eli Lilly and Company in the second quarter valued at $749,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Freedom Capital raised Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, February 10th. Jefferies Financial Group set a $1,300.00 price objective on Eli Lilly and Company and gave the stock a "buy" rating in a research note on Friday, March 13th. Loop Capital set a $1,200.00 price objective on Eli Lilly and Company in a research note on Tuesday, February 10th. Leerink Partners boosted their price objective on Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the stock an "outperform" rating in a research note on Thursday, February 5th. Finally, Wells Fargo & Company boosted their price objective on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an "overweight" rating in a research note on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $1,224.59.

Eli Lilly and Company Stock Down 1.8%

Shares of NYSE:LLY opened at $905.73 on Thursday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The business has a 50 day simple moving average of $976.09 and a two-hundred day simple moving average of $979.89. The firm has a market capitalization of $855.75 billion, a PE ratio of 39.47, a price-to-earnings-growth ratio of 1.07 and a beta of 0.51. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. During the same quarter in the previous year, the business earned $5.32 earnings per share. The company's revenue for the quarter was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly received another buy rating tied to its newly launched obesity pill, which analysts expect to be a global bestseller — this supports revenue upside from weight‑loss therapies. Eli Lilly Stock (LLY) Gets Another Buy Rating as Its Obesity Pill Hits the Market
• Positive Sentiment: Lilly agreed to acquire CrossBridge Bio for up to $300M, adding preclinical ADC technology to bolster oncology pipeline optionality and long‑term growth prospects. Lilly to acquire CrossBridge Bio for up to $300m
• Positive Sentiment: Distribution and access expand as digital care platform Shed adds Foundayo™ (Lilly’s oral GLP‑1 for weight management), which can help broaden patient uptake beyond specialty clinics. Shed Adds Foundayo™ to Its Platform, Expanding Oral GLP-1 Access for Patients Nationwide
• Positive Sentiment: Lilly is licensing its TuneLab AI platform to partners (e.g., Vasa Therapeutics), highlighting additional revenue streams and R&D leverage from proprietary AI tools. Vasa Therapeutics Partners with Lilly TuneLab to Power AI/ML-Driven CAMKII Inhibitor Platform
• Neutral Sentiment: Macro/valuation commentary remains mixed — some bullish, long‑term price targets (e.g., Forbes piece on LLY to $2,000) reflect confidence in blockbuster drugs but are speculative. LLY Stock To $2,000?
• Neutral Sentiment: Market reports note the stock is down today despite broader market gains — a short‑term price action update for traders. Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
• Negative Sentiment: Competitive risk is rising: Novo Nordisk’s new partnership with OpenAI to accelerate drug discovery reinforces its capability to close gaps in the weight‑loss market and may pressure Lilly’s market share and investor sentiment. NVO Inks Deal With OpenAI for Speedy Drug Discovery Globally, Stock Up

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.